Implantable lead for septal placement of pacing electrodes

Information

  • Patent Grant
  • 8204606
  • Patent Number
    8,204,606
  • Date Filed
    Monday, June 23, 2008
    16 years ago
  • Date Issued
    Tuesday, June 19, 2012
    12 years ago
Abstract
A pacing lead having a lead body configured into a pre-formed J-shape. The lead includes a pacing electrode coupled to an intermediate portion of the lead body and located distally from a bottom of the pre-formed J-shape. The lead is adapted to be placed within a heart in a J-shaped configuration with the electrode positioned proximate a ventricular septum or a right ventricular outflow tract such that at least a portion of the distal end of the lead body is located within a pulmonary artery. In one embodiment, the distal end of the lead is configured to be passively fixated within the pulmonary artery. Another aspect includes a lead body wherein a section of the intermediate portion of the lead body is less stiff than adjacent sections of the lead body. The lead includes a pacing electrode coupled to the intermediate portion of the lead body and located distally from the less stiff section. The lead is adapted to be placed within a heart in a J-shaped configuration with the less stiff section near a bottom of the J-shape such that the electrode is positioned proximate a ventricular septum or a right ventricular outflow tract and at least a portion of the distal end of the lead body is fixated within a pulmonary artery.
Description
FIELD OF THE INVENTION

This invention relates to the field of medical leads, and more specifically to an implantable lead.


BACKGROUND

Leads implanted in or about the heart have been used to reverse certain life threatening arrhythmia, or to stimulate contraction of the heart. Electrical energy is applied to the heart via the leads to return the heart to normal rhythm. Leads have also been used to sense in the atrium or ventricle of the heart and to deliver pacing and defibrillation pulses to the atrium or ventricle.


Permanent transvenous pacing is performed using a lead positioned within one or more chambers of the heart. One or more leads may be positioned in the ventricle or in the atrium through a subclavian vein, and the lead terminal pins are attached to a pacemaker which is implanted subcutaneously. One approach to heart pacing is to place an electrode in the apex of the right ventricle. The lead is held in place either passively or actively using a helix, for example.


Another approach is to place the electrode against the high ventricular septum or outflow tract. However, current leads require a lead placed with the electrode in such a position to be actively fixated. This possibly may result in trauma to the heart from cyclical heart motion, micro-dislodgement, and relatively higher pacing thresholds.


SUMMARY

A lead body configured into a preformed J-shape. The lead includes a pacing electrode coupled to an intermediate portion of the lead body located distally from a bottom of the pre-formed J-shape. The lead is adapted to be placed within a heart in a J-shaped configuration with the electrode positioned against a ventricular septum or a right ventricular outflow tract such that at least a portion of the distal end of the lead body is located within a pulmonary artery. In one embodiment, the distal end of the lead is configured to be passively fixated within the pulmonary artery.


Another aspect includes a lead body wherein a section of the intermediate portion of the lead body is less stiff than adjacent sections of the lead body. The lead includes a pacing electrode coupled to the intermediate portion of the lead body and located distally from the less stiff section. The lead is adapted to be placed within a heart in a J-shaped configuration with the less stiff section near a bottom of the J-shape such that the electrode is positioned proximate a ventricular septum or a right ventricular outflow tract and at least a portion of the distal end of the lead body is fixated within a pulmonary artery.


Another aspect includes a method including inserting the lead through a right ventricle and into a pulmonary artery such that the pacing electrode is proximate a ventricular septum or a ventricular outflow tract and the distal end is within the pulmonary artery.


One or more embodiments of the methods and apparatus disclosed herein can result in lower pacing thresholds, better electrode contact, prevent micro-dislodgement of pacing/sensing electrodes, offer better reliability, and ease of implanting and explanting the lead.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a view of a lead, according to one embodiment, implanted within a heart.



FIG. 2 shows a distal portion of a lead according to one embodiment.



FIG. 3 shows a distal portion of a lead according to one embodiment.



FIG. 4 shows a distal portion of a lead according to one embodiment.



FIG. 5 shows a view of a lead, according to one embodiment, implanted within a heart.



FIG. 6 shows an intermediate portion of a lead according to one embodiment.



FIG. 7 shows a view of a lead, according to one embodiment, implanted within a heart.





DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that other embodiments may be utilized and that structural changes may be made without departing from the scope of the present invention. Therefore, the following detailed description is not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.



FIG. 1 shows a view of a lead 100 implanted within a heart 10. Heart 10 generally includes a superior vena cava 12, a right atrium 14, a right ventricle 16, a right ventricular apex 17, a ventricular septum 18, and a ventricular outflow tract 20, which leads to a pulmonary artery 22. In one embodiment, lead 100 is adapted to deliver pacing pulses to heart 10. Lead 100 is part of an implantable system including a pulse generator 110.


Pulse generator 110 can be implanted in a surgically-formed pocket in a patient's chest or other desired location. Pulse generator 110 generally includes electronic components to perform signal analysis and processing, and control. Pulse generator 110 can include a power supply such as a battery, a capacitor, and other components housed in a case. The device can include microprocessors to provide processing, evaluation, and to determine and deliver electrical shocks and pulses of different energy levels and timing for ventricular defibrillation, cardioversion, and pacing to heart 10 in response to cardiac arrhythmia including fibrillation, tachycardia, and bradycardia.


In one embodiment, lead 100 is designed for septal placement of the pacing electrode with a distal end of the lead located in the pulmonary artery. Lead 100 can pace and sense at the His bundle/septum/outflow tract, and there is less trauma than caused by active fixation.


In one embodiment, lead 100 includes a lead body 105 extending from a proximal end 107 to a distal end 109 and having an intermediate portion 111. Lead 100 includes one or more conductors, such as coiled conductors, to conduct energy from pulse generator 110 to heart 10, and also to receive signals from the heart. The lead further includes outer insulation 112 to insulate the conductor. The conductors are coupled to one or more electrodes, such as electrodes 124 and 126. Lead terminal pins are attached to pulse generator 110. The system can include a unipolar system with the case acting as an electrode or a bipolar system.


In one embodiment, lead 100 is adapted for septal placement of one or more of the electrodes 124 and 126 while utilizing pulmonary artery 22 for lead fixation. Lead 100 can pace and sense at the interventricular septum 18 or ventricular outflow tract 20. For example, in one embodiment electrodes 124 and 126 are coupled to intermediate portion 111 of the lead. Electrodes 124 and 126 can be pacing/sensing electrodes, such as ring electrodes, designed to deliver a pacing pulse of approximately 0.5 volts at 0.1 milliseconds to approximately 15 volts at 2.0 milliseconds to septum 18 in a bipolar pulsing system. Electrodes 124 and 126 are proximal from distal end 109 and are located on the lead to sense or pace high on the ventricular septum (above apex 17), or in the ventricular outflow tract when the lead is implanted. Advantageously, lead 100 allows such a high placement while not requiring active fixation.


When inserted in the heart and positioned such that electrodes 124 and 126 are against ventricular septum 18, some leads require active fixation. However, active fixation can cause repeated trauma to the endocardial tissue because of the cyclical motion of the heart, and thus may have possible micro-dislodgement and increase defibrillation and pacing thresholds.


In one embodiment, lead body 105 including a preformed, biased J-shape 120 formed in the intermediate portion 111 of the lead body. J-shape 120 is located such that electrode 124 and 126 are located distally from a bottom 122 of the pre-formed J-shape 120. Pre-formed J-shape 120 can be in either 2D or 3D. J-shaped portion 120 of lead 100 allows for better septal/electrode contact. To pre-form the lead, the lead can be manufactured such that it is biased in the J-shape. Thus, the lead naturally reverts to the J-shape when it is implanted. For example, the lead body can be formed in the pre-biased shape or the conductor coils can be formed in the pre-biased shape to bias the lead body into the J-shape. When implanted, the bottom 122 of the J-shape 120 is within the right ventricle 16 and electrodes 124 and 126 are positioned proximate ventricular septum 18 above apex 17, or positioned in right ventricular outflow tract 20 such that at least a portion of the distal end 109 of the lead body is located within a pulmonary artery 22. The pre-formed J-lead design enhances the septal electrode stability and contact. It can help result in low pacing thresholds because of better electrode contacts.


In one embodiment, at least a portion of lead 100 can include an anti-thrombosis coating 140, such as Hypren or polyethleneglycol for example. Coating 140 can be placed on the lead, for example on one or more of the electrodes, or on the distal portion of the lead, or on other segments of the lead.


In one embodiment, lead 100 can include a sensor 150, such as a cardiac output sensor, mounted to the intermediate portion of the lead 100. Sensor 150 can be implanted to such a location within the outflow tract 20 to monitor cardiac output. In one example, cardiac output monitoring sensor 150 can be placed proximate the distal end of the lead to be placed within the pulmonary artery. Sensor 150 can be coupled to pulse generator 110 through a conductor.


In one embodiment, sensor 150 can be a flow speed sensor, allowing the system to know how fast the blood is going through the artery. For example, sensor 150 can be a metal ring, coil, or fin. Such a component would have resistance properties such that if a pulse of energy was sent through the component, the component would heat up, which would in turn increase the electrical resistance of the component. The electrical resistance could be monitored over time to determine how it changes as the blood flow going past it cools it down to blood temperature. The faster the blood flow, the faster the component will cool down and hence the faster the resistance should drop. This cool down or resistance change can be correlated to the blood flow. In other embodiments, sensor 150 can be a pressure sensor. In some embodiments, sensor 150 can include a CO2 or O2 sensor.


In these embodiments, sensor 150 can be used to determine blood flow to allow the position of electrodes 124 and 126 to be optimized. For example, the cardiac output can be used to change the position of the electrode either during or after implantation. Moreover, sensor 150 can be utilized during therapy. For example, if the flow rate goes down the system can deliver a pulse or increase the voltage of the pulse.


In some embodiments, lead 100 can be configured to allow both a stylet or catheter delivery. For example, an opening can be left through the middle of the lead to allow a stylet to be used.


In one embodiment, distal end 109 is adapted for being passively fixated within a pulmonary artery. For example, as will be discussed below, a pre-formed biased distal portion 109 can be provided. In some embodiments, to be discussed below, an active fixation technique is utilized. Some embodiments utilize neither passive nor active fixation, relying on the J-shape 120 and gravity to hold the electrodes 124 and 126 in place against the septum.



FIG. 2 shows distal portion 109 of lead 100 according to one embodiment. In this example, a pre-formed, biased shape 130 includes a J-shaped curve 142 at a distal tip of the lead body. I-shaped curve 142 can be positioned within pulmonary artery 22 or in one of the branch arteries off of the pulmonary artery to passively fixate the distal end of the lead within the pulmonary artery.



FIG. 3 shows distal portion 109 of lead 100 according to one embodiment. In this example, pre-formed, biased shape 130 includes a spiral configuration 144. The pre-formed, biased shape generally can include at least two lead surfaces (such as surfaces 132 and 136, for example) which are dimensioned and positionable such that the surfaces 132 and 136 contact opposing walls of the pulmonary artery.



FIG. 4 shows distal portion 109 of lead 100 according to one embodiment. In this example, pre-formed, biased shape 130 includes an S-shaped configuration 146.


In various embodiments, pre-formed bias shape 130 of distal end 109 can include a curved shape such as an S-shape, a C-shape, a J-shape, an O-shape, and other non-linear shapes adapted for contacting one or sides of the pulmonary artery to provide sufficient fixation of the lead. Lead 100 is more reliable because the lead is easier to implant and explant because of the passive fixation which is allowed by the shape of the distal portion of lead 100. For example, passive fixation allows for easier adjustment of electrode placement, and is easier to explant. Moreover, there is less trauma or perforation to endocardium tissue, which can yield lower pacing thresholds. Also, there is less trauma to the septal/outflow tract caused by active fixation at the septal/outflow tract location.



FIG. 5 shows a front view of a lead 200 according to one embodiment. Lead 200 includes some of the components discussed above for lead 100, and the above discussion is incorporated herein. Lead 200 extends from a proximal end 207 to a distal end 209 and includes an intermediate portion 211. Lead 200 can be implanted in heart 10 with distal end 209 located within the pulmonary artery and electrodes 124 and 126 positioned against the septum 18 or within the ventricular outflow tract 20.


In one embodiment, lead 200 includes a section 210 of the intermediate section 211 of the lead which is less stiff than adjacent sections 212 and 216 of the lead body. Lest stiff section 210 is located proximally from electrodes 124 and 126. When lead 200 is positioned in the heart with distal portion 209 in the pulmonary artery, the soft, or less stiff section 210 allows the lead to naturally fall into place and contact the septum due to gravity. Lead 200 is adapted to be placed within a heart in a J-shaped configuration with the less stiff section near a bottom 218 of the J-shape such that electrodes 124 and 126 are positioned proximate ventricular septum 18 or right ventricular outflow tract 20 and at least a portion of the distal end 209 of the lead body is located within a pulmonary artery. The less stiff section 210 provides means on the lead body for reducing any forces caused by heart motion to be transferred to a site of the electrode.


In one embodiment, the less stiff section 210 includes a different, more pliable material than the material of adjacent sections 212 and 216. Again, when the lead is positioned in the heart, the soft segment allows the lead to naturally fall into place and contact the septum due to gravity. The less stiff section 210 enhances the septal electrode stability and contact. Also, it reduces or eliminates the forces and motion (caused by heart motion) transferred to the site of the septal pacing electrodes 124 and 126. This can result in lower pacing thresholds because of better electrode contact.


In this example, as S-shaped passive fixation configuration is provided for distal end 109. In other embodiments, passive techniques as shown above in FIGS. 2-4, or the active technique discussed below can be utilized.



FIG. 6 shows a portion of lead 200 according to one embodiment. In one example, less stiff section 210 includes a smaller diameter than the adjacent sections 212 and 216. In other embodiments, less stiff section 210 can be formed by providing a lead wall having a different internal diameter thickness, or by providing a less stiff conductor coil at that location.


In one example use of one or more of the leads discussed herein, the lead is inserted through the right ventricle and into the pulmonary artery using a guiding catheter or a stylet. The lead is positioned until the distal end of the lead is in the pulmonary artery and electrodes are positioned against the septum. The lead can then be fixated there by one of the passive techniques discussed above. When the pulse generator detects a need for pacing, the pulse is delivered via electrodes 124 or 126 in either a bipolar or unipolar system.



FIG. 7 shows a view of a lead 300 according to one embodiment, implanted within a heart 10. Lead 300 can include one or more of the components discussed above for leads 100 and 200 and the above discussions are incorporated herein. In one embodiment, lead 300 is adapted to be actively fixated within the pulmonary artery 22 utilizing a helix 310, or other active fixation mechanism. In one embodiment, lead 300 includes radiopaque markers 320 near the distal tip to help a physician guide the lead when viewed under fluoroscopy. One embodiment includes a drug elution member 330, which can elude steroids, for example, to reduce inflammatory response of the tissue. In some embodiments, lead 300 does not include either the pre-formed J-shape 120 (FIG. 1) or the less stiff section 210 (FIG. 5) of the leads discussed above. Lead 300 can be an unbiased, flexible lead relying on helix 310 for fixation within the pulmonary artery. In other embodiments, the active fixation technique can be used with the leads discussed above. In some embodiments, active fixation can be provided in addition to or in place of the passive fixation design discussed above.


It is understood that the above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims
  • 1. A lead comprising: a lead body extending from a proximal end to a distal end and having an intermediate portion, wherein the intermediate portion of the lead body is biased to revert to a pre-formed J-shape when implanted;the distal end of the lead body including a pre-formed J-shaped fixation curve configured for passive fixation within the pulmonary artery; anda pacing electrode coupled to the intermediate portion of the lead body and located distally from a bottom of the pre-formed J-shape, wherein the lead body is configured to be placed within a heart in a J-shaped configuration with the electrode coupled to a ventricular septum or a right ventricular outflow tract and with at least a portion of the distal end of the lead body located within a pulmonary artery.
  • 2. The lead of claim 1, wherein at least a portion of the lead includes an anti-thrombus coating.
  • 3. The lead of claim 1, further comprising a sensor mounted proximate the distal end of the lead body to monitor cardiac output through the pulmonary artery.
  • 4. A lead comprising: a lead body extending from a proximal end to a distal end and having an intermediate portion, the distal end including a pre-formed fixation curve configured for being fixated within a pulmonary artery, the pre-formed fixation curve having an S-shaped configuration, a J-shaped configuration or a spiral shaped configuration, and wherein the intermediate portion of the lead body is biased to revert to a pre-formed J-shape when implanted; anda pacing electrode mounted to the intermediate portion of the lead body, wherein a base of the J-shaped lead body is proximally located relative to the electrode such that the electrode contacts a ventricular septum when the lead is positioned in a heart with the intermediate section within the right ventricle and the distal end fixated within the pulmonary artery.
  • 5. The lead of claim 4, further comprising a sensor mounted to the lead body to monitor cardiac output.
  • 6. A lead comprising: a lead body extending from a proximal end to a distal end and having an intermediate portion with a stiffness less than the proximal and distal ends, wherein the intermediate portion of the lead body is biased to revert to a pre-formed J-shape when implanted; anda pacing electrode coupled to the intermediate portion of the lead body and located distally from a bottom of the pre-formed J-shape, wherein the lead body is configured to be placed within a heart in a J-shaped configuration with the electrode coupled to a ventricular septum or a right ventricular outflow tract and with at least a portion of the distal end of the lead body located within a pulmonary artery;wherein the distal end of the lead body includes a pre-formed, biased distal tip configured for passively fixating the distal end of the lead body within a pulmonary artery, the pre-formed, biased distal tip including an S-shaped configuration, a J-shaped configuration or a spiral shaped configuration.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 10/325,433, filed on Dec. 19, 2002 now U.S. Pat. No. 7,392,094, which is incorporated herein by reference in its entirety.

US Referenced Citations (138)
Number Name Date Kind
3209305 Bruckner et al. Sep 1965 A
3974834 Kane Aug 1976 A
3995623 Blake et al. Dec 1976 A
4046151 Rose Sep 1977 A
4307928 Petlock, Jr. Dec 1981 A
4332259 McCorkle, Jr. Jun 1982 A
4402328 Doring Sep 1983 A
4458677 McCorkle, Jr. Jul 1984 A
4471777 McCorkle, Jr. Sep 1984 A
4488561 Doring Dec 1984 A
4576162 McCorkle Mar 1986 A
4582056 McCorkle, Jr. Apr 1986 A
4595009 Leinders Jun 1986 A
4627439 Harris Dec 1986 A
4632125 Webler et al. Dec 1986 A
4641656 Smits Feb 1987 A
4643201 Stokes Feb 1987 A
4759378 Swendson et al. Jul 1988 A
4957111 Millar Sep 1990 A
4986270 Cohen Jan 1991 A
4991603 Cohen et al. Feb 1991 A
4998975 Cohen et al. Mar 1991 A
5000190 Petre Mar 1991 A
5014696 Mehra May 1991 A
5029585 Lieber et al. Jul 1991 A
5044375 Bach et al. Sep 1991 A
5103821 King Apr 1992 A
5107834 Ideker et al. Apr 1992 A
5144960 Mehra et al. Sep 1992 A
5176137 Erickson et al. Jan 1993 A
5217318 Peppel Jun 1993 A
5224491 Mehra Jul 1993 A
5226427 Buckberg et al. Jul 1993 A
5246014 Williams et al. Sep 1993 A
5314462 Heil et al. May 1994 A
5336252 Cohen Aug 1994 A
5342413 Hirschberg et al. Aug 1994 A
5353800 Pohndorf et al. Oct 1994 A
5387233 Alferness et al. Feb 1995 A
5387234 Hirschberg Feb 1995 A
5403351 Saksena Apr 1995 A
5405374 Stein Apr 1995 A
5409469 Schaerf Apr 1995 A
5411527 Alt May 1995 A
5423772 Lurie et al. Jun 1995 A
5423806 Dale et al. Jun 1995 A
5423865 Bowald et al. Jun 1995 A
5433729 Adams et al. Jul 1995 A
5433742 Willis Jul 1995 A
5447519 Peterson Sep 1995 A
5476498 Ayers Dec 1995 A
5476499 Hirschberg Dec 1995 A
5476500 Fain et al. Dec 1995 A
5531779 Dahl et al. Jul 1996 A
5545204 Cammilli et al. Aug 1996 A
5571159 Alt Nov 1996 A
5609621 Bonner Mar 1997 A
5628779 Bornzin et al. May 1997 A
5634936 Linden et al. Jun 1997 A
5639276 Weinstock et al. Jun 1997 A
5643338 Bornzin et al. Jul 1997 A
5643580 Subramaniam Jul 1997 A
5649974 Nelson et al. Jul 1997 A
5674217 Wahlstrom et al. Oct 1997 A
5674272 Bush et al. Oct 1997 A
5683447 Bush et al. Nov 1997 A
5693081 Fain et al. Dec 1997 A
5697965 Griffin, III Dec 1997 A
5713867 Morris Feb 1998 A
5728140 Salo et al. Mar 1998 A
5769858 Pearson et al. Jun 1998 A
5772693 Brownlee Jun 1998 A
5788647 Eggers Aug 1998 A
5800498 Obino et al. Sep 1998 A
5803928 Tockman et al. Sep 1998 A
5843117 Alt et al. Dec 1998 A
5843141 Bischoff et al. Dec 1998 A
5851226 Skubitz et al. Dec 1998 A
5861023 Vachon Jan 1999 A
5871530 Williams et al. Feb 1999 A
5897584 Herman Apr 1999 A
5902331 Bonner et al. May 1999 A
5922014 Warman et al. Jul 1999 A
5925073 Chastain et al. Jul 1999 A
5932360 Hazlitt et al. Aug 1999 A
5994444 Trescony et al. Nov 1999 A
6006122 Smits Dec 1999 A
6021354 Warman et al. Feb 2000 A
6038472 Williams et al. Mar 2000 A
6043273 Duhaylongsod Mar 2000 A
6055457 Bonner Apr 2000 A
6076014 Alt Jun 2000 A
6093982 Kroll Jul 2000 A
6117128 Gregory Sep 2000 A
6122553 Idekar et al. Sep 2000 A
6129750 Tockman et al. Oct 2000 A
6132390 Cookston et al. Oct 2000 A
6159237 Alt et al. Dec 2000 A
6161029 Spreigl et al. Dec 2000 A
6178355 Williams et al. Jan 2001 B1
6223087 Williams Apr 2001 B1
6245064 Lesh et al. Jun 2001 B1
6256541 Heil et al. Jul 2001 B1
6363286 Zhu et al. Mar 2002 B1
6363287 Brabee et al. Mar 2002 B1
6445954 Olive et al. Sep 2002 B1
6463323 Conrad-Vlasak et al. Oct 2002 B1
6501992 Belden et al. Dec 2002 B1
6532378 Saksena et al. Mar 2003 B2
6643546 Mathis et al. Nov 2003 B2
6718211 Smits Apr 2004 B2
6741893 Smits May 2004 B2
6760619 Helland et al. Jul 2004 B1
6882886 Witte et al. Apr 2005 B1
7238883 Zarembo Jul 2007 B2
7392094 Zhang et al. Jun 2008 B2
7512440 Ortega et al. Mar 2009 B2
7555351 Zhang et al. Jun 2009 B2
7890188 Zhang et al. Feb 2011 B2
20010020179 Audoglio Sep 2001 A1
20010031987 Saksena et al. Oct 2001 A1
20020049485 Smits Apr 2002 A1
20020065544 Smits May 2002 A1
20040054390 Zarembo et al. Mar 2004 A1
20040122496 Zhang et al. Jun 2004 A1
20040122497 Zhang et al. Jun 2004 A1
20040122498 Zhang et al. Jun 2004 A1
20040147994 Zhang et al. Jul 2004 A1
20040260374 Zhang et al. Dec 2004 A1
20040260375 Zhang et al. Dec 2004 A1
20050149155 Scheiner et al. Jul 2005 A1
20050149156 Libbus et al. Jul 2005 A1
20050228469 Zarembo et al. Oct 2005 A1
20060089694 Zhang et al. Apr 2006 A1
20070205014 Zarembo Sep 2007 A1
20070299492 Zhang et al. Dec 2007 A1
20080262586 Zhang et al. Oct 2008 A1
20090264974 Zhang et al. Oct 2009 A1
Foreign Referenced Citations (6)
Number Date Country
3-168162 Jul 1992 JP
09-508054 Aug 1997 JP
2001-522287 Nov 2001 JP
2002-126095 May 2002 JP
WO 9615665 May 1996 WO
WO 9848896 Nov 1998 WO
Related Publications (1)
Number Date Country
20080262586 A1 Oct 2008 US
Continuations (1)
Number Date Country
Parent 10325433 Dec 2002 US
Child 12144247 US